Related Experiment Video
Updated: Oct 11, 2025

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
COVID-19, Pre-Eclampsia, and Complement System
Chiara Agostinis1, Alessandro Mangogna1, Andrea Balduit2
1Institute for Maternal and Child Health, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Burlo Garofolo, Trieste, Italy.
Insights
COVID-19 infection in pregnant women can lead to pre-eclampsia by damaging endothelial cells and activating the complement system. Complement inhibitors show promise for treating both COVID-19 and pre-eclampsia.
Area of Science:
- Immunology
- Obstetrics
- Virology
Background:
- COVID-19 causes multi-organ failure, endothelial cell injury, and thrombotic events.
- The complement system interacts with contact and coagulation systems, worsening SARS-CoV-2 infection outcomes.
- Overlapping immunopathological mechanisms exist between COVID-19 and pre-eclampsia (PE).
Purpose of the Study:
- To review the role of the complement, contact, and coagulation systems in SARS-CoV-2 infection during pregnancy.
- To explore the link between COVID-19 infection and the development of pre-eclampsia.
- To examine potential therapeutic strategies targeting these systems.
Main Methods:
- Review of existing literature on COVID-19, pre-eclampsia, and related immune/coagulation pathways.
- Analysis of the cross-talk between complement, contact, coagulation, and endothelial cell activation in SARS-CoV-2 infection.
- Examination of the impact of SARS-CoV-2 on endothelial cells via ACE2 and TMPRSS2.
Main Results:
- SARS-CoV-2 infection can dysregulate endothelial cells, leading to dysfunction, vascular damage, hyperinflammation, and hypercoagulability.
- Increased bradykinin levels due to ACE2 inhibition by SARS-CoV-2 exacerbate endothelial dysfunction.
- Complement system dysregulation in pregnancy can result in PE-like syndromes following SARS-CoV-2 infection.
Conclusions:
- Pregnant women with COVID-19 are at increased risk for pre-eclampsia due to overlapping pathological pathways.
- Complement inhibitors, particularly those targeting C3 or MASP-2, represent promising therapeutic options for COVID-19 and associated pre-eclampsia.
- Understanding these interconnected systems is crucial for managing pregnant patients with COVID-19.
Abstract:
COVID-19 is characterized by virus-induced injury leading to multi-organ failure, together with inflammatory reaction, endothelial cell (EC) injury, and prothrombotic coagulopathy with thrombotic events. Complement system (C) via its cross-talk with the contact and coagulation systems contributes significantly to the severity and pathological consequences due to SARS-CoV-2 infection. These immunopathological mechanisms overlap in COVID-19 and pre-eclampsia (PE). Thus, mothers contracting SARS-CoV-2 infection during pregnancy are more vulnerable to developing PE. SARS-CoV-2 infection of ECs, via its receptor ACE2 and co-receptor TMPRSS2, can provoke endothelial dysfunction and disruption of vascular integrity, causing hyperinflammation and hypercoagulability. This is aggravated by bradykinin increase due to inhibition of ACE2 activity by the virus. C is important for the progression of normal pregnancy, and its dysregulation can impact in the form of PE-like syndrome as a consequence of SARS-CoV-2 infection. Thus, there is also an overlap between treatment regimens of COVID-19 and PE. C inhibitors, especially those targeting C3 or MASP-2, are exciting options for treating COVID-19 and consequent PE. In this review, we examine the role of C, contact and coagulation systems as well as endothelial hyperactivation with respect to SARS-CoV-2 infection during pregnancy and likely development of PE.
Related Concept Videos
Complement System
Hormonal Regulation
Nephrotic Syndrome I : Introduction
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension II: Pathophysiology

